The board of directors biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.61 per share on the company's common stock for the second quarter of 2020, it disclosed on Tuesday.
This dividend is payable on 7 July 2020 to shareholders of record at the close of business as of 15 June 2020.
Merck said it continues to be at the forefront of research to prevent and treat diseases that threaten people and animals, including cancer, infectious diseases, HIV and Ebola, as well as emerging animal diseases.
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results